July 2011
AlgiPharma has together with partners Smerud Medical Research and Simbec Research been awarded a EUROSTARS grant for a €4,6 million project.
June 2011
The first cystic fibrosis patient has been enrolled into AlgiPharma’s clinical phase 2 trial. The study is performed at cystic fibrosis centers in the UK and Ireland. The study title is: A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis chronically colonised with Pseudomonas aeruginosa.
April 2011
AlgiPharma has been granted permission to start its clinical phase 2 trial in cystic fibrosis patients by the Irish Medicines Board. The study title is: A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis chronically colonised with Pseudomonas aeruginosa.
April 2011
AlgiPharma has received a research grant from CFF, the Cystic Fibrosis Foundation, to perform an in-vitro study of its proposed cystic fibrosis medicine. The grant is administered by the Cystic Fibrosis Foundation Therapeutics Inc., a subsidiary of the CFF. The research shall be performed in the United Kingdom.
About the Cystic Fibrosis Foundation: The Cystic Fibrosis Foundation is the leading organization devoted to curing and controlling cystic fibrosis. Headquartered in Bethesda, Md. USA, the Foundation funds CF research, has 80 chapter and branch offices throughout the United States, and supports and accredits a nationwide network of 115 CF care centers, which provide vital treatments and other CF resources to patients and families. For more information, visit www.cff.org.
To advance the search for a cure, CFFT has invested nearly $230 million in promising scientific research in the pharmaceutical and biotechnology industries since 1998. As a result, the Foundation has nearly 30 potential therapies in its drug discovery and development pipeline. Any one of these could have a profound impact on the lives of people with cystic fibrosis.
March 2011
AlgiPharma has been granted permission to start its clinical phase 2 trial in cystic fibrosis patients by the United Kingdom Medicines and Healthcare products Regulatory Agency. The study title is: A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis chronically colonised with Pseudomonas aeruginosa.
February 2011
AlgiPharma has won approval from the relevant UK and Irish ethics committees to start its clinical phase 2 trial in cystic fibrosis patients. The study title is: A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis chronically colonised with Pseudomonas aeruginosa.
September 2010
AlgiPharma presents seven posters and gives two oral presentations at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 12-15, in Boston, MA, USA.
June 2010
AlgiPharma announces that results from in vitro testing have shown a significant increase in the susceptibility of a variety of bacterial species and strains to antibiotics when co-administered with AlgiPharma’ lead pharmaceutical product candidate, OligoG CF-5/20. In particular, tests conducted with certain strains of Burkholderia cepacia resulted in an up to 7-fold increase in the bacterial susceptibility to antibiotics when co-administered with OligoG CF-5/20. Read more
January 2010
AlgiPharma announces excellent results from clinical phase I for respiratory diseases. OligoG CF-5/20 was well tolerated when administered by inhalation to 28 healthy subjects. All adverse events monitored were mild and transient. No serious adverse events, no deaths, no discontinuations. Read more
ClinicalTrials.gov
October 2009
AlgiPharma presents poster “Effect of alginate oligomers on biofilm disruption” on North American Cystic Fibrosis Conference (NACFC). Studies were done at Cardiff University, Cardiff, UK. View the poster
September 2009
A clinical phase I for AlgiPharma’s prospective medicine for Cystic Fibrosis (respiratory diseases), OligoG CF-5/20, was approved by the Medicines and Healthcare Product Regulatory Agency, MRHA, and is initiated at SIMBEC (UK) and scheduled to be concluded before the end of the year. Results are set to be reported in the first quarter of 2010.
June 2008
The Research Council of Norway (Norges Forskningsråd (NFR)) has awarded AlgiPharma grants for two new - projects “Biofilm” and “Epipharm II” representing a continuation and expansion of the NFR support for AlgiPharma’s alginate oligomer research efforts. These grants are administered under the NFR program for User directed Innovation Arena.
September 2007
AlgiPharma’s medicinal product “Alginate oligosaccharide (G-block) fragment” has been designated as an orphan medicinal product for the following indication: treatment of Cystic Fibrosis. The European Medicines Agency’s Committee for Orphan Medicinal Products recommended that AlgiPharma’s application be accepted by the Commission of the European Communities. The Commission gave final approval on September 14th.
August 2006
On the initiative of FMC BioPolymer AS, AlgiPharma was established, financed and began operating as an independent company. AlgiPharma is a biopharmaceutical company that aims to develop medicinal products within the areas of respiratory diseases, wound healing and other infectious diseases.
|
|
|
